Latest Commercial Sales News

Proteomics International has begun a controlled release of two Promarker diagnostic tests through Healius in Western Australia and the Northern Territory. National commercial sales are targeted for Q2 FY27, but uptake and revenue remain difficult to estimate at this early stage.

Phoslock Environmental Technologies has advanced a new range of lanthanum-enhanced phosphorus-binding products showing up to four times the capacity of current offerings, with pilot and manufacturing tests confirming strong performance and low lanthanum release. Field trials are underway, aiming for commercial sales in 2027.

Memphasys has secured product registration for its Felix™ System in Turkey, marking the start of commercial sales with an initial order of 100 cartridges and two consoles. The move taps into a large assisted-reproduction market with strong growth potential.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Li-S Energy reported a reduced net loss of $4.9 million in FY26, propelled by major technological advances and a $7.8 million ARENA grant to scale manufacturing. The company secured key regulatory approvals and expanded strategic defence partnerships, positioning itself at the forefront of sovereign lithium sulfur battery supply.